adalimumab

Therapies for hidradenitis suppurativaAlthough hidradenitis suppurativa is a disease that is extremely impactful and burdensome several medical therapies have been proven to be effective and safe.
Express Scripts’ 2016 Drug Trend Report: 7 things to knowReport highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.
Adalimumab effective but not a cure for uveitisAdalimumab (Humira, AbbVie), an immunosuppressive biologic therapy, improves the symptoms of noninfectious active uveitis, but causes some adverse events and does not cure the disease, researchers say.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Assessing the impact of biosimilars on cost, qualityA new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.
Hidradenitis suppurativa misunderstood and underdiagnosedMisconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.”
Can you maintain response after biologic holiday?Melinda Gooderham, M.D., MSc, FRCPC Patients might stop taking their biologic medications for a variety of reasons. When patients do stop their biologic therapy, clinicians need to consider that some biologic therapies are better at recapturing response than others. learn more
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.